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The glyoxalase pathway functions to detoxify reactive dicarbonyl compounds, most importantly methylglyoxal.
The glyoxalase pathway is an antioxidant defense mechanism that is essential for neuroprotection. Excessive
concentrations of methylglyoxal have deleterious eﬀects on cells, leading to increased levels of inﬂammation and
oxidative stress. Neurodegenerative diseases – including Alzheimer's, Parkinson's, Aging and Autism Spectrum
Disorder – are often induced or exacerbated by accumulation of methylglyoxal. Antioxidant compounds possess
several distinct mechanisms that enhance the glyoxalase pathway and function as neuroprotectants. Flavonoids
are well-researched secondary plant metabolites that appear to be eﬀective in reducing levels of oxidative stress
and inﬂammation in neural cells. Novel ﬂavonoids could be designed, synthesized and tested to protect against
neurodegenerative diseases through regulating the glyoxalase pathway.

1. Introduction
The gyloxalase pathway is a well-conserved antioxidant defense
system found in all cells of the body [1–4]. The glyoxalase pathway
facilitates the neutralization of highly reactive and oxidizing dicarbonyl
molecules, with methylglyoxal (MG) being the most critical target [5].
Carbonyl molecules target the brain due to its high rate of metabolism
and low antioxidant defense capacity [6]. The brain also contains high
concentrations of oxidizable substrates including polyunsaturated fats
and metal ions [7]. Accumulation of MG damages and inﬂuences the
cellular environment, leading to a state of chronic inﬂammation and
oxidative stress [4,5,8–12]. The glyoxalase system is present in all cells
in the body, but has especially important functions in the brain [3,13].
Oxidative stress (OS) results from an imbalance between electrophilic prooxidative molecules and the capacity of antioxidants to reduce
and neutralize the free radicals [14]. It is a chronic state of inﬂammation that prevents the proper function of integral cellular processes, causing irreversible damage to cells [10,14,15]. Excessive oxidative stress in the brain leads to accelerated aging, and impacts the
severity of neurodegenerative diseases [16,17]. High levels of oxidative
stress inﬂuence the onset and progression of aging, Alzheimer's disease
(AD), Parkinson's disease (PD), and autism spectrum disorder (ASD)

[18,19]. Eﬃcient and active function of the glyoxalase pathway is
critical to reducing oxidative stress mediated damage to brain cells
[20–24]. Flavonoid antioxidant compounds possess the capacity to
enhance the glyoxalase pathway through several distinct mechanisms,
including modulation of critical signaling pathways involved in cell
proliferation [25–27].
OS and inﬂammation gradually increase during aging [28,29].
However, high levels of OS and inﬂammation can accrue over time and
are contributing factors to aging and neurodegenerative diseases including AD, PD, ASD, dementia, and psychiatric disorders [1,30].
Hallmarks of these diseases are also shared in glyoxalase pathway
dysfunction: increased reactive oxygen species (ROS) production,
apoptosis, and oxidation of molecules [2,9,31,32]. The onset and progression of neurodegenerative disease can be inﬂuenced by substituents
of the glyoxalase pathway. For example, inhibition of glo 1 reduces
neuronal viability and increases accumulation of advanced glycation
endproducts (AGEs), while overexpression of glo 1 reduces formation of
ROS [4,21,33,34]. Aging is correlated with a decrease in glo 1 concentration and activity [16,35]. Depletion of GSH by MG can prevent
astrocytic detoxiﬁcation of reactive molecules and lead to an increase in
oxidized proteins, lipids, and amino acids [21,36]. Increasing the capacity and eﬃciency of the glyoxalase pathway appears to be an
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Fig. 1. The glyoxalase pathway functions to detoxify methylglyoxal. Methylglyoxal reacts with reduced glutathione (GSH) to
form a hemithioacetal (HTA). Glo 1 uses the hemithioacetal as a
substrate to form S,D-lactylglutathione. Glo-2 reacts with the resulting intermediate compound, and the pathway produces Dlactate. This step also reduces glutathione and recycles it into the
pathway.

signaling [6,43]. It also plays a vital role in DNA and protein repair and
synthesis, metal ion metabolism, and cellular survival [36,47]. It is one
of the most important endogenous antioxidants, and proper levels are
paramount to a cell's health and normal functioning.

eﬀective means of reducing the onset and severity of aging and neurodegenerative disease [37].

1.1. Glyoxalase pathway
2. Diseases of glyoxalase pathway

The glyoxalase pathway consists of proteins glyoxalase 1 (glo 1) and
glyoxalase 2 (glo 2), reduced glutathione (GSH), and a dicarbonyl
substrate (Fig. 1) [4,16,21]. The pathway is a series of two reactions
that neutralize MG to produce D-lactate. MG spontaneously reacts with
GSH to form a hemithioacetal. It is catalyzed by glo 1 into an intermediate compound S,D-lactylglutathione. Glo 2 catalyzes the ﬁnal reaction producing D-lactate and recycling GSH into the pathway [21].
The rate of glyoxalase activity varies based on the type, location, and
environment of the cell [30,38,39] . The glyoxalase pathway is a dynamic system able to respond to the constantly changing cellular environment. The glyoxalase pathway is in every cell, and is implicated in
cancer cell proliferation, maintenance of blood glucose, liver enzymes,
and cardiovascular and renal function [40].
MG is a byproduct of glycolysis and the metabolism of proteins and
lipids [5]. MG is an electrophile and highly reactive glycating agent,
able to irreversibly modify proteins, lipids, and nucleic acids, forming
advanced glycation end products (AGEs) [5,10]. Structural modiﬁcations to molecules can signiﬁcantly reduce function, and may lead to
degradation by immune cells [41]. MG is stable molecule, and membrane permeable in certain forms. Excess MG is able to leak into surrounding cells and tissues [42]. In a functioning glyoxalase system, MG
is degraded and prevented from accumulating [21]. Under a state of
dysfunction - caused by damage to pathway constituents, high levels of
metabolism, or high levels of carbonyl precursors present - MG will be
produced at a higher level and disrupt macromolecular functions [58].
Accumulation of MG has many deleterious eﬀects that lead to a cellular
environment with high levels of inﬂammation and oxidative stress (OS)
[4].
MG is directly able to cause impairment to the glyoxalase system
[5]. ROS can be directly produced during its formation and degradation
[43–45]. MG can also deplete the concentration of antioxidant enzymes
[46]. MG is also able to modulate important signaling pathways, resulting in excessive ROS, inﬂammation, apoptosis, and ultimately
chronic oxidative stress, leading to death of brain cells, tissues, and
disease [5].
MG can neutralize enzymes that are able to catalyze reactions and
scavenge substrates, including GSH [1,5,39,40,42] . MG can also increase NADPH oxidase activity, preventing the reduction of GSH and it's
recycling back into the glyoxalase pathway [1,6,39,40,42]. GSH protects against OS by directly scavenging ROS, and regulates redox

Impaired function of the glyoxalase pathway – especially in the
brain - has very serious ramiﬁcations for cells and tissue. Aging,
Alzheimer's, and Parkinson's, (Fig. 2) are neurodegenerative diseases
that can be caused or inﬂuenced by elevated levels of oxidative stress
[4,48,49]. These diseases are complex and multifactorial, and can be a
cause and consequence of disrupted glyoxalase pathway function. Increased levels of oxidative stress can be a result of glyoxalase system
impairment [19,50,51]. Psychiatric disorders like ASD, schizophrenia,
anxiety, bipolar disorder, and depression can also be a cause/eﬀect of
impaired glyoxalase function [52 –54]. The glyoxlase pathway exerts
control over antioxidant defense mechanisms that are paramount for
homeostasis of the redox environment of the cell [55,56]. Disrupted
function of the glyoxalase pathway can lead to an inﬂammatory environment contributing to the pathogenesis of neurodegenerative disease [23,40]. MG can cause mutations of DNA and nucleic acids, culminating in telomere shortening, loss of heterochromatin, altered gene
expression patterns, and mitochondrial dysfunction [23,57,58].
Oxidative stress results from the disequilibrium between levels of
prooxidant molecules produced and the ability of a biological system to
detoxify and neutralize the reactive molecules [14]. OS is a chronic,
self-perpetuating state of damage to cells and increased inﬂammation
resulting from the corresponding immune response [27,43]. Glyoxalase
pathway dysfunction can result in the accumulation of MG in cells [3].
The build up of MG has a direct link to the propagation of OS and
inﬂammation, and is an inﬂuencing factor in neurodegenerative disease
[8,23,48].
The main source of damage from OS is ROS mediated inﬂammation
[43]. ROS and free radicals have unpaired electrons, and act as nucleophiles to attack macromolecules. The donor molecule gives its
electrons to ROS [14]. The molecules attacked by ROS have structural
modiﬁcations, which causes the molecules to have limited or no function [5]. Under normal conditions, ROS are used in cell signaling and
defense against pathogens by macrophages; their damaging eﬀects are
caused when they have accumulated past a normal amount [10].
Glyoxalase cycle dysfunction is one perpetrator to blame for the increased ROS production.
AGEs can be formed from modiﬁed proteins, lipids, or nucleic acids
[59]. Structural changes can reduce biological activity of
466
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Fig. 2. Methylglyoxal is a highly reactive compound with many deleterious eﬀects on neurons. MG mediates the increased production of ROS, free radicals, pro-inﬂammatory cytokines,
and advanced glycation end products, has damaging eﬀects on mitochondria function and nucleic acids, and increases apoptosis through multiple means, including signaling pathway
activation. The resulting increase in oxidative stress and inﬂammation plays a major role in aging and development of neurodegenerative disease including Alzheimer's, Parkinson's,
Autism Spectrum Disorder, and Huntington's.

macromolecules, and are often identiﬁed as misfolded or damaged and
labeled for destruction [59,60]. Nucleic acid (and mtDNA) can undergo
strand breaks, impaired repair mechanisms, and permanent mutations
[61]. Lipids are easily oxidizable, and membranes, being rich in lipids,
are prone to these modiﬁcations [43].
Research has shown a link between MG accumulation, glyoxalase
system activity, and disease [21]. Glyoxalase activity is diﬀerentially
expressed based on cell type and state. Glyoxalase activity has found to
increase with age, but subjects over 50 years old exhibit a decline in
glyoxalase I [62]. The low glo 1 activity in aging leads to a higher level
of dicarbonyl compounds, and it was also discovered that decreasing
glo 1 levels correlated with an accumulation of AGEs [35]. Elevated
levels of MG leads to inﬂammation, OS, apoptosis, and DNA damage
[40,63].
It has been shown the pathological hallmarks of AD and PD are
colocalized to AGEs [41,63,64]. In a comparison of glyoxalase activity
between healthy and AD brain tissue, the AD group had a signiﬁcantly
lowered glo 1 activity, at the mRNA and protein level [35].
MG is highly reactive and also cytotoxic. MG inhibits cell growth,
and induces cell death at higher concentrations [65]. MG prevented
proper hippocampal neurogenesis, adversely impacting neural diﬀerentiation, survival, and proliferation, it is believed due to reduced
hippocampal BDNF levels [66]. MG concentration can act as a biomarker of severity of disease [23]. AD patients were found to have
increased MG in CSF compared to healthy aged controls [64].

the determination of disease progression through biomarkers of oxidative stress and disease. Markers denoting oxidized substrates, nuclear
abnormalities are directly related to the extent and progression of aging
[15].
4. Alzheimer's disease
Alzheimer's disease is the most common neurodegenerative disorder, and the leading cause of dementia in the elderly [67]. It is a
multifactorial disease characterized by progressive neural loss of the
hippocampus and cortex, memory and learning impairment, and
changes in behavior and personality [19,68]. It has pathogenic hallmarks of beta amyloid (Aβ) plaques and neuroﬁbrillary tangles (NFT)
[69]. Cognitive impairment reﬂects synapse loss in dentate gyrus of
hippocampus, and neuron loss in frontal and parietal lobe of cortex
[70–72].
The amyloid precursor protein (APP) is a membrane protein thought
to be involved in plasticity, synapse formation and repair, and export of
metal ions [68]. The APP present in the brain can be cleaved by three
diﬀerent secretases [73,74]. Cleavage of APP ﬁrst by alpha secretase
and then gamma-secretase results in a functional protein; while cleavage by beta-secretase results in Aβ. The product formed from this
improper cleavage – beta amyloid - will aggregate into plaques, and
disrupt function of normal cells [19,74]. These Aβ plaques can be
modiﬁed by MG and AGEs, forming crosslinks, aﬀording them stability
and defense against protease cleavage [75,76]. Aβ plaques are very
stable and have long lives - The progression of AD is preceded 15 years
by appearance of Aβ deposits [23,41]. Aβ plaques will disrupt neuron
function, and induce ROS production, ultimately leading to inﬂammation, damage to cell/tissue, and apoptosis [48,69,77,78].
Aβ aggregates will clump around neurons and prevent their proper
function [67]. The Aβ plaques also attract and activate microglia,
causing them to cluster and localize around the plaques [21,67]. These
immune cells release signals inducing cellular toxicity [68]. The Aβ
plaques cause additional production of AGEs, which will reduce the
activity of enzymes and proteins (especially in mitochondria) [41].
These AGEs will lead to increased ROS production, which increases the
production of APP [23,68]. Aβ plaques can also disrupt redox signaling
by interacting with metal ions in active sites of macromolecule,

3. Aging
Aging is a progressive decline in physiological and metabolic
functions of an organism [10]. The process is characterized by chronic,
low level inﬂammation that progresses over time. The rate of aging can
be accelerated and inﬂuenced by genetic and environmental factors.
Age is also the biggest risk factor for Alzheimer's and Parkinson's [19].
Age is correlated with an increase in ROS formation, oxidized proteins
and lipids, and apoptosis [14]. Also, during normal aging OS will increase while glutathione activity decreases. Decreasing glo 1 levels are
strongly correlated with increasing levels of AGEs, and glo 1 levels drop
in accordance to age [16].
The extent of damages can only be viewed posthumously, requiring
467
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preventing proper function [48].
Impairment of the glyoxalase system can have a direct impact on the
severity of AD [22,73]. Studies have shown glyoxalase I levels decrease
with increased aging and severity of AD [14]. The imbalance of antioxidant aﬀects causes a shift to a state of OS. Accumulation of MG and
AGEs in the Alzheimer's disease brain is very deleterious [75]. Tissue
from AD brain shows high amounts of AGEs and oxidized lipids and
proteins, which is a marker of inﬂammation [41]. There is a correlation
with the amount of MG/AGEs localized to speciﬁc brain regions and
severity of AD [75].
NFT are ﬁlaments of bundled proteins formed from a disruption in
the microtubule network of cells [67,74]. Microtubule associated protein tau is responsible for promoting and stabilizing microtubule formation in cells, however hyperphosphorylation of tau destabilizes and
disrupts the proper assembly of microtubules [79,80]. Proteins aggregate and oligomerize forming toxic NFT, causing the death of neurons in the area [81].
Increased MG levels, apoptosis, and OS contribute to production of
Aβ and hyperphosphorylation of tau [5]. MG can also disrupt cell signaling pathways that control kinases and phosphatases used to regulate
phosphorylation of tau [1,59]. Aβ has an inﬂuential and contributing
role in the production of NFT, and they are both stable molecules prone
to glycation [76]. MG derived AGEs aggregate in NFT and beta amyloid
plaques [19]. AGE crosslinking in Aβ aﬀords it insolubility and protease
resistance [75,76]. MG modiﬁed Aβ in plaques has a longer half-life,
allowing it to accumulate more AGE modi ﬁcations, which causes more
Aβ to form [9,67].

depleted levels of GSH, and disruption of GSH metabolism has been
found to progress neurological disorders [36].
6. Autism spectrum disorder
Autism Spectrum Disorder is a multifactorial neurodevelopmental
disorder categorized by impairment in communication, language, social
behaviors and relationships [24]. The basis for ASD is still misunderstood, but there is evidence of cellular and metabolic dysfunction inﬂuenced by mitochondrial activity [95]. There are also physical abnormalities and alterations in ASD brains. Over 100 genes contribute to
ASD, mutations in any of these can lead to ASD [20]. All genes participate in diﬀerent brain functions controlled by the brain areas, which
aﬀect emotional formation, learning and memory, cognitive control,
and social orientation [96].
Autistic brains also have a lowered level of viable GABA producing
Purkinje neuron cells [97]. MG derived AGEs and ROS will modify the
Purkinje neurons, leading to their ultimate death [98]. The OS exhibited in ASD can be a cause of loss of these integral neuron cells [53].
Combined with the high amounts of lipid peroxidation, the OS exhibited in ASD brains could be alleviated by glyoxalase dependent MG
detoxiﬁcation [99,100].
DNA and mtDNA mutations and abnormalities are common in ASD
[97,101]. These can cause impaired electron transport chain (ETC) and
mitochondria function (membrane potential/polarization, molecule
transport, mito protein translocation, and apoptosis) [102,103]. ASD is
also categorized by an abnormal immune response; this can have negative eﬀects on brain growth factors, development, and neural transmitters [52,104]. Patients with autism demonstrated activated micro/
astro glia and increased levels of proapoptotic cytokines [52]. Patients
of ASD had signiﬁcantly lower ratios of mitochondria proteins bcl-2/
bak, which is an indicator of increased cell death and decreased function [24].
Abnormal neural brain maturation found in ASD is inﬂuenced by
mitochondria dysfunction and MG mediated cellular signaling
[97,101]. ASD can lead to chronic immune activation, causing OS in the
ASD brain [101]. These can be caused by disequilibrium in MG and
glyoxalase signaling [105]. Patients with autism have lower reduced
glutathione levels, however it is not known if it is due to a deﬁcit in
synthesis or regeneration of glutathione [100].

5. Parkinson's disease (PD)
Parkinson's is the second common neurodegenerative disease. It is
characterized by degeneration of dopamine producing neurons in the
substantia nigra [19]. This leads to a decrease of dopamine levels in
areas of the brain associated with movement, caused by deregulation in
ganglion cell circuits [81–88] . The disease is characterized by motor
deﬁciencies - including tremors, rigidity, and slowness of movement –
and cognitive deﬁciencies [49]. Pathological markers of Parkinson's
include the accumulation of alpha synuclein into Lewy bodies [57,84].
The degeneration of dopaminergic neurons and oxidation of dopamine
causes altered mitochondrial respiration, inducing a state of oxidative
stress in neural tissue [49,89].
Alpha synuclein (AS) is a protein located in presynaptic terminals of
neurons that functions in recycling and storage of neurotransmitters
[17]. Under conditions of inﬂammation and oxidative stress, AS proteins misfold and accumulate into aggregates [81,90]. The aggregates
of misfolded AS oligimorize into Lewy bodies. These aggregates are
cytotoxic, disrupt connections between neurons, and deplete levels of
neurotransmitters [81]. AS also reacts with dopamine quinones leading
to accumulation of toxic ﬁbrils in the dopaminergic neurons
[80,89,90]. Accumulation of AS and Lewy bodies have a detrimental
impact on mitochondria activity, causing an elevation of ROS production and deﬁcit in metabolic activity [57].
Neural dopamine can become oxidized if there are high levels of MG
derived AGEs [49]. These dopamine quinones have impaired activity,
and contribute to the degeneration of neurons [18,90]. MG accumulation can lead to production of ROS and depletion of NADPH, which is
critical for reducing glutathione for use in the glyoxalase pathway
[81,91,92]. The decline in synthesis of dopamine also causes disruption
in vesicle transport, and makes the cell prone to damage and mtDNA
mutations [84].
There is a correlation between progression of disease and biomarkers of oxidative stress [93,94]. Post mortem studies of PD brains
show high levels of oxidized substrates, and colocalization of AGEs to
Lewy bodies [89]. AD and PD have diﬀerent clinical pathologies but
share similar causes and symptoms and Aβ plaques can be commonly
found in PD brains [19]. Patients with PD have been found to have

7. Flavonoid function
Antioxidants are compounds - when present at a lower concentration compared oxidizable substrate - that delay or prevent oxidation of
the substrate [14,106]. Antioxidants act as nucleophiles to reduce an
oxidative molecule to prevent its interaction with another molecule
[14,107]. Endogenous antioxidants produced by the body function in
prevention and neutralization of ROS and free radicals, repair of damaged macromolecules, and redox signaling [14]. Exogenous antioxidants consumed through food and drink also play an important role
in cellular defense and survival, and have shown to aid the body in
combating oxidative stress and inﬂammation [108,109].
Flavonoids are secondary plant metabolites commonly found in
fruits and vegetables [25]. Flavonoids are a family of polyphenol antioxidants that are eﬀective in combating high levels of OS [10,14].
Flavonoids are distinguished by the presence of multiple phenol rings, C
to C double bonds, and hydroxyl groups [26]. These structural characteristics confer the antioxidant function of ﬂavonoids, and the
number and location of hydroxyl groups inﬂuence the biological activity of the ﬂavonoids [106,110] . The lipophilicity is also inﬂuenced
by structure, which allows some ﬂavonoids to favorably pass through
the blood brain barrier [111–114]. The hydroxyl groups are critical for
antioxidant activity, and scavenge free radicals and ROS by donation of
a proton [114].
This class of antioxidant molecules possesses several distinct
468
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inﬂammatory and degenerative diseases. A correlation exists between
ﬂavonoid consumption and low levels of dementia and neural pathology [127]. Intake of ﬂavonoids can have a protective eﬀect on
neural cells in many diseased states [127,128]. Silymarin and naringin
are ﬂavonoids that have shown eﬃcacy in protection against excitotoxicity in dopaminergic neurons. Silymarin protected mice against
1-methyl-4-phenylpyridinium (MPP+) induced toxicity by attenuating
production of inﬂammatory cytokines, and prevented mitochondrial
dysfunction [127]. Naringin protected neural cells from toxicity mediated by 6-Hydroxydopamine (6-OHDA), mediated by an increase in
Nrf2 activation [127]. Morin has also shown to mitigate the damage
caused by ischemia and stroke by downregulating expression and release of proinﬂammatory cytokines [118]. A grape powder extract was
shown to reduce anxiety-like behavior, depression, and memory impairments caused by elevated OS [129].

mechanisms of protection from oxidative stress. Flavonoids can directly
scavenge and neutralize ROS and free radicals, increase intracellular
inﬂux, and modulation of sigGSH, prevent glutamate mediated Ca
naling pathways involved in cellular survival [4,25,26]. Directly neutralizing ROS prevents the oxidation of proteins, amino acids, lipids,
metal ions, and other macromolecules. Oxidative modiﬁcation irreversibly changes structure and prevents normal function of macromolecules. The presences of ﬂavonoids are able to protect these molecules from MG mediated modiﬁcation into AGEs. Glutathione is a major
constituent of the glyoxalase pathway, and one of the most important
endogenous antioxidants for neutralization of dicarbonyl compounds
and maintaining redox balance in cells [26]. Flavonoid treatment was
found to increase GSH concentration, and increased mRNA transcript
levels of both GSH constituent subunits [4,26]. GSH is also an essential
substrate of astrocytic detoxiﬁcation in the brain [47]. GSH is also
critical for prevention of glutamate mediated apoptosis [115]. Elevated
levels of glutamate are cytotoxic, and lead to apoptosis via inﬂux of
Ca . Excess glutamate depletes GSH, leading to a decrease in activity
of glo 1 [25]. Flavonoids have shown to reduce intracellular Ca
inﬂux in the presence of toxic levels of glutamate [25].
Flavonoid molecules can regulate signaling pathways to modulate
cellular, immune, and metabolic processes [4]. Flavonoids are able to
modulate a variety of pathways including NF-κB, MAPK, ERK, and Nrf2
[116,117]. Flavonoid molecules can modulate and reduce expression of
proapoptotic and proinﬂammatory products of genes [118,119]. ROS
are used as signaling molecules during immune responses, and the
presence of antioxidants can prevent ROS mediated phosphorylation of
molecules and pathway targets, preventing their activation and transcription [109]. Flavonoids can also inhibit activation of kinases and
phosphatases that would contribute to apoptotic cell death
[120,121,4]. After a ﬂavonoid is oxidized by a free radical, the resulting
quinones are involved in signaling pathways involved in cellular antioxidant and repair activities (Fig. 3).
Flavonoids can have a direct impact [122] and inﬂuence on the
function of the gyloxalase pathway. Flavonoids can bind and scavenge
free radicals, and also increase the intracellular levels of GSH, while
ﬂavonoids are able to scavenge free radicals, in physiological concentrations they are not eﬀectively able to scavenge free radicals [25].
The most eﬀective form of neuroprotection by ﬂavonoids is preventing
formation of free radicals by modulation of cell signaling pathways
[109,123,124]. Flavonoid antioxidant treatment can lower the intracellular levels of free radicals and ROS, and also enhance the performance of the glyoxalase system by modulating signaling pathways
involved in cellular proliferation and survival, glutathione synthesis
and expression of antioxidative proteins [4,10,14,25,121].
Morin is a ﬂavonoid that has shown to have eﬀective anti-inﬂammatory and anti-tumor function [118]. Morin was able to block the
activation of NF-κB pathway by ROS and inﬂammatory cytokines,
preventing a signaling cascade resulting in cell death [121]. Morin
exerted its control over the signaling pathway by inhibiting TNF induced NF-κB activation by inhibiting degradation of IκBα, and morin
was also able to inhibit TNF mediated p65 nuclear translocation
[120,125]. Morin inhibited phosphorylation of Akt in a breast cancer
cell line, preventing metastases and tumor proliferation [116]. Morin
was shown to decrease survival of cancer cells, while increasing viability of normal endothelial cells [116]. These compounds are involved
in the pAkt - NF-κB signaling pathways in neuronal cells to enhance the
glyoxalase expression [4].
Flavonoids have shown eﬀectiveness in modulation of glyoxalase
pathway and MG detoxiﬁcation. Our previous research has shown
treatment with catechin, morin, and quercetin was able to attenuate the
eﬀects of MG toxicity while retaining cellular function. The ﬂavonoids
increased glo 1 activity and GSH concentration, while reducing the
concentration of MG [4,126].
While a lack of ﬂavonoids does not cause any disease, Exogenous
antioxidants can inﬂuence cellular health and oﬀer protection against

8. Mechanistic interference
When under states of stress and cytotoxicity, cells initiate antioxidant defense mechanisms. Nuclear factor erythroid 2-related factor 2
(Nrf2) activation leads to the transcription of proteins involved in
counteracting oxidative damage [56]. The Nrf2 pathway is activated
during elevated OS. Unstimulated Nrf2 is bound to Keap1 in the cytoplasm, and subsequently ubiquitinated and degraded [130]. Under
states of OS, ROS disrupt the association between Keap1 and Nrf2. Nrf2
is released from the complex, and translocates to the nucleus to bind the
antioxidant response element (ARE), leading to the production of antioxidant molecules [55]. (Fig. 4) Gene products function in an antioxidant, anti-inﬂammatory, and neuroprotective fashion [119]. Among
the products are glo 1, heme oxygenase-1 (HO-1), gamma-glutamylcysteine synthetase (GCS), and glutathione-S-transferase.
Keap 1 is a negative regulator of Nrf2. Keap 1 and Cullin-3 contain
Nrf2 in the cytoplasm of cells. Cullin-3 ubiquitinates Nrf2 and it is
transported to proteasome for degradation. High levels of OS and free
radicals phosphorylate targets on Keap 1 and Cullin-3 and disrupt the
Keap1-Cullin-3 degradation system. Nrf2 is not degraded, and builds up
in the cytoplasm until it is translocated to the nucleus and binds to ARE
[131]. Nrf2 is critical for mediating expression of protective genes in
response to MG induced OS and toxicity, and Nrf2 expression has been
showed to suppress accumulation of AGEs [56]. Neurons treated with a
Nrf2 activator were protected from MG mediated damage [132]. The
Nrf2 signaling pathway increased intracellular GSH levels, and increased the glyoxalase pathway's detoxiﬁcation of MG protecting cells
from OS mediated damage [133]. Neuron cells treated with N-acetyl
serotonin showed enhanced nuclear translocation of Nrf2 from the cytoplasm [134]. Nrf2 activators have shown beneﬁts in PD animal
models, Nrf2 expression prevented 1-methyl-4-phenyl 1,2,3,6 tetrahydropyridine (MPTP) induced toxicity in cells [135]. Flavonoids are
able to indirectly induce Nrf2 expression by activation of kinase pathways resulting in phosphorylation of Nrf2 and induction of dependent
genes [56,136]. Nrf2 also provided a stress-responsive defense against
AGEs and lead to transcriptional control of glyoxalase [56] and a
temporal dynamic reciprocal regulation of Nrf2 and glo 1 was observed
during disease development [137]. Mangiferrin also upregulated glo 1
through activating Nrf2/ARE signaling pathway [138].
Flavonoids are able to modulate proinﬂammatory signaling pathways to prevent OS and apoptosis [139]. Paraoxygenase-2 (PNO2) is an
enzyme involved in neuroprotection by preventing OS mediated damage in mitochondria. Flavonoids can modulate the JNK/AP-1
pathway to increase expression of PNO2 [111]. Flavonoids are able to
inhibit expression of TNF-α by modulating NF-κB, inducing expression
of antioxidant molecules like PNO2. PNO2 is primarily located in the
mitochondria. PNO2 exerts its neuroprotection primarily through protecting against mitochondrial mediated oxidative stress [112].
Flavonoids can directly scavenge free radicals, but they have limited
accessibility to the brain; antioxidant concentration in the brain is too
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Fig. 3. Flavonoid antioxidants possess several distinct of cellular neuroprotection. Flavonoids reduced
the amount of inﬂammation and oxidative stress in
the cellular environment through multiple means.
Flavonoid compounds directly scavenge free radicals
and ROS, increase intracellular concentration of GSH
and antioxidant molecules, modulate NF-κB signaling pathways to reduce apoptosis, and reduce
glutamate mediated Ca intracellular inﬂux. These
actions of ﬂavonoids directly enhance the glyoxalase
pathway.

9. Conclusion

low to have a signiﬁcant impact on direct scavenging. Flavonoids exert
their protective eﬀects by modulation of cell signaling pathways and
activation of cellular antioxidant defense mechanisms [112]. Flavonoids also inhibit AGE formation by preventing formation/presence of
dicarbonyl compounds, and also attenuate damage [118]. Flavonoids
were found to reduce MG mediated OS, and enhance the glyoxalase
pathway activity [126].

The glyoxalase pathway is an integral part of the body's antioxidant
system. Dysregulation can have deleterious and catastrophic events,
leading to high levels of OS, and also neurodegenerative disease. This
seemingly innocuous pathway found in all cells of our body can be
responsible for production and formation of toxic intermediaries that
alter a cell's normal function and leading to Alzheimer's disease,
Parkinson's disease, ASD and Aging. Flavonoids were found to be
Fig. 4. Inactive Nrf2 is bound to Keap1 and Cullin-3
in the cytoplasm. Cullin-3 ubiquitinates Nrf2 and is
targeted for proteosomal degradation. Elevated levels of electrophiles and ROS disrupt the ability of
Cullin-3 to degrade Nrf2. Nrf2 builds up in the cytoplasm, and translocates to the nucleus. It forms a
complex with Maf and binds to ARE, inducing the
transcription of antioxidant defense molecules to
protect the cell from cytotoxicity.
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involved in the reduction of oxidative stress through mechanisms
regulated by the glyoxalase pathway. Flavonoid compounds have
shown the ability to scavenge ROS and regulate cell signaling pathways
integral for antioxidant defense mechanisms and cellular survival. The
glyoxalase pathway is a promising drug target for neurodegenerative
diseases. Drug discovery [4,140–144] and delivery [145–147] processes could be explored in this target against neurodegenerative diseases. Novel ﬂavonoids could be designed, synthesized, and tested to
protect neurodegenerative diseases through glyoxalase pathway.
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